Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. director Regev Guy filed an initial ownership statement showing direct holdings of options to purchase Ordinary Shares and a small number of shares. He reports options over 16,000 shares at an exercise price of $2.18 per share plus several smaller, higher-priced option grants and 8 Ordinary Shares. The options were granted under the company’s share option plans, with some fully vested and others vesting in scheduled quarterly installments through 2030.
Can-Fite BioPharma Ltd. filed a prospectus registering for resale up to 3,294,898 ordinary shares represented by 1,647,449 ADSs, consisting primarily of shares issuable upon exercise of repriced warrants. The offering is by selling shareholders; the company will receive proceeds only if warrants are exercised for cash. The ADS ratio is 2 ordinary shares per ADS and there are 4,285,093 ordinary shares outstanding as of March 30, 2026.
Can-Fite BioPharma Ltd. files a Form F-3 resale registration to permit selling shareholders to resell up to 3,294,898 ordinary shares represented by 1,647,449 ADSs, consisting primarily of shares issuable upon exercise of repriced warrants.
The registration covers New Warrants and Placement Agent Warrants with an exercise price of $5.00 per ADS, exercisable for two years from the registration effective date; holders may exercise on a cashless basis under specified conditions. The company will not receive proceeds from resale transactions but may receive proceeds if warrants are exercised for cash (full cash exercise would yield approximately $8.01M). Shares outstanding were 4,285,093 ordinary shares as of March 30, 2026; pro forma outstanding assuming full warrant exercise is 7,579,991 ordinary shares.
Can-Fite BioPharma Ltd. files a post-effective amendment consolidating two prior Form F-1 registration statements to register resale of up to 67,879 ordinary shares represented by 33,940 ADSs. The prospectus covers (I) 9,546 ordinary shares (4,773 ADSs) from the January 2023 placement agent warrants and (II) 58,333 ordinary shares (29,167 ADSs) from the July 2025 placement agent warrants. Each ADS represents two ordinary shares after a January 5, 2026 ratio change. The company will not receive proceeds from resale by the selling shareholders; it may receive proceeds only if warrants are exercised for cash. Ordinary shares outstanding were 4,285,093 as of March 30, 2026.
Can-Fite BioPharma Ltd. filed a post-effective amendment to register resale of up to 67,879 ordinary shares represented by 33,940 ADSs. The registration aggregates (i) 9,546 ordinary shares (4,773 ADSs) from the January 2023 placement agent warrants and (ii) 58,333 ordinary shares (29,167 ADSs) from the July 2025 placement agent warrants. Each ADS represents two ordinary shares. The company will not receive proceeds from sales by the selling shareholders; however, it may receive proceeds if outstanding warrants are exercised for cash. Shares outstanding were 4,285,093 ordinary shares as of March 30, 2026.
Can-Fite BioPharma Ltd. reports that its veterinary partner Vetbiolix has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Piclidenoson for osteoarthritis in 118 client-owned dogs. The 90-day, oral twice-daily trial focuses on mobility and pain reduction using validated scoring tools.
Vetbiolix funds all development and regulatory costs for registering Piclidenoson in companion animals and has exercised its option for a full licensing agreement. Can-Fite is eligible for upfront, milestone and royalty payments representing projected revenues of up to $325 million over the next decade, subject to successful development and commercialization. Top-line Phase 2 results are expected in Q3 2026.
Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company developing orally available small molecules targeting the A3 adenosine receptor (A3AR) for cancer, liver and inflammatory diseases. Its ADSs trade on NYSE American under the symbol CANF, each ADS representing two ordinary shares.
The company has no approved products and has incurred recurring losses, with net losses of approximately $9.8 million in 2025, $7.9 million in 2024 and $7.6 million in 2023, leading to an accumulated deficit of about $176.2 million as of December 31, 2025. Cash and cash equivalents were $5.5 million and short-term deposits $3.0 million at that date, which management believes will fund operations for twelve months from the report’s issuance, but additional capital will be needed thereafter.
As of December 31, 2025, 2,618,425 ordinary shares were outstanding. On January 2, 2026, Can-Fite effected a 1‑for‑3,000 reverse split of its ordinary shares on the TASE and concurrently changed its ADS ratio to one ADS for two ordinary shares, effectively a one‑for‑twenty reverse ADS split. The filing details extensive risk factors, including clinical, regulatory, financing, competition, intellectual property and NYSE American continued-listing risks.
Can-Fite BioPharma reported 2025 results showing continued investment in its pipeline and a wider loss. Revenues were $0.41 million, down about 40% from $0.67 million in 2024, reflecting lower recognition of upfront distribution payments.
Research and development expenses rose to $6.69 million and general and administrative expenses to $3.66 million, driving a net loss of $9.83 million versus $7.88 million a year earlier. Cash, cash equivalents and short-term deposits totaled $8.54 million as of December 31, 2025, helped by financing activity, and the company received an additional $4.3 million from warrant exercises and an inducement in March 2026.
Clinically, a Phase 2a pancreatic cancer trial of Namodenoson met its primary safety endpoint, and more than 30% of heavily pretreated patients were alive at the latest cut-off. In hepatocellular carcinoma, one Namodenoson-treated patient has remained cancer-free for over nine years, while a Phase 3 HCC study and a Phase 2b trial in metabolic liver disease are ongoing. The company also highlighted a favorable case in decompensated cirrhosis, expansion into obesity indications, and new patents in several countries.